Area of research
Rheumatology · Immunology
Research interest
Research interests include Medicine, Psoriatic arthritis, Ankylosing spondylitis, Internal medicine, Etanercept, and Rheumatology.
2018 update of the EULAR recommendations for the management of Behçet's syndrome
Timing of onset affects arthritis presentation pattern in antisyntethase syndrome.
PubMed 2018cited by 57position: middle
Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology.
PubMed 2018cited by 33position: middle
Clinical and ultrasonographic predictors for achieving minimal disease activity in patients with psoriatic arthritis: the UPSTREAM (Ultrasound in PSoriatic arthritis TREAtMent) prospective observational study protocol
The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis
Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey
The Definition and Measurement of Axial Psoriatic Arthritis
Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study
Remission in Nonradiographic Axial Spondyloarthritis Treated with Anti-tumor Necrosis Factor-α Drugs: An Italian Multicenter Study
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis
Obesity and reduction of the response rate to anti–tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine